Clinical Deep Phenotyping Study (CDP)

ID

2

DZPG Site

München/Augsburg
General Information
Status

Ongoing (II): Recruitment and data collection ongoing

Description

In line with the Research Domain Criteria initiative, the Clinical Deep Phenotyping (CDP) study is using a multimodal approach to reveal the neurobiological underpinnings of clinically relevant schizophrenia subgroups (characterized with MINI interview according to DSM-V) by performing a broad transdiagnostic clinical characterization with standardized clinical scores and neurocognitive assessments (BACS), multimodal neuroimaging (sMRI, rsfMRI, ASL, MRS, DTI), electrophysiological assessments (rsEEG, P300, TMS-based neurophysiology), retinal investigations (OCT, ERG), and omics-based analyses of blood (i.e. neuroplasticity, neurodegenerative and neuroinflammatory biomarkers) and cerebrospinal fluid. Moreover, to bridge the translational gap in biological psychiatry the study includes the assessment of polygenic risk scores and in vitro investigations on human-induced pluripotent stem cells, which are available from a subset of participants.

Paper

https://pubmed.ncbi.nlm.nih.gov/37215661/

Trial Number

DRKS00024177

Contact
PI

Dr. Elias Wagner

Further PIs

Florian Raabe (florian.raabe@med.uni-muenchen.de) Daniel Keeser (daniel.keeser@med.uni-muenchen.de)

Survey Results
Is it an interventional or non-interventional study?
  • Non-interventional
Specification of study type
  • Case-control
  • Longitudinal
Is it a mono- or multicentric study?

Multicentric

Number of sites

3

Is it a single or multi country study?

Single

Which country?

Germany

Who are participants?
  • General population
  • Patients with specific diseases
Which diseases? (ICD-11 classification)
  • Mental, behavioural or neurodevelopmental disorders (06)
Mental, behavioural or neurodevelopmental disorders (ICD-11 classification)
  • Schizophrenia or other primary psychotic disorders
  • Mood disorders
Recruitment setting
  • General population
  • Hospital
  • Outpatient
Target sample size

1000

Obtained sample size

500

Start of recruitment

2021

Minimum age of participants

18

Maximum age of participants

65

Data sources for the study
  • Biological samples
  • Administrative databases
  • Cognitive measurements
  • Genealogical records
  • Imaging data
  • Medical records
  • Interview
  • Questionnaire
  • Physiological/biochemical measurements
  • Omics technology
Is it planned to share the data?

Undecided, it is not yet known if data will be made available

Are further follow-ups planned?

Yes

Is there consent to re-contact participants?

Yes

Is the implementation of further study components possible?

Yes

View raw data